Protara Therapeutics Inc's ROA from the second quarter of 2026 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Protara Therapeutics Inc's ROA in the second quarter of 2026?
Protara Therapeutics Inc recorded a cumulative net loss of $-67 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -36.87%.

However, within the Healthcare sector 477 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3698, from total ROA ranking in the fourth quarter of 2025 at 4335.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-2.58 %	165.15 %	43.58 %	39.53 %	60.35 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-67	-58	-52	-48	-45
Return On Assets (TTM)	-36.87 %	-31.78 %	-36.11 %	-36.3 %	-36.44 %
TARA's Total Ranking	# 3698	# 4335	# 3856	# 3889	# 3993
Total Assets (TTM) in million	177	249	146	157	181
Seq. Total Assets Change	-29.25 %	71.35 %	-7.5 %	-13.13 %	92.56 %
Seq. Net Income Change	-	-	-	-	-

TARA's 5 Years Annual ROA >> Back to TARA Management Effectiveness >> Compare TARA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 58
Sector	# 478
Overall	# 3741

Return On Assets Statistics
High	Average	Low
-9.91 %	-45.1 %	-94.28 %
(Sep 30 2015)		(Sep 30 2017)

Financial Statements
Protara Therapeutics Inc's Assets	$ 177 million	TARA's Balance sheet
Protara Therapeutics Inc's Income	$ -22 million	Quarterly TARA's Income Statement
TARA's Income by Division		See TARA's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2026	(Mar 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022
Y / Y Total Assets Change	37.65 %	-6.35 %	60.35 %	-1.42 %	-33.59 %
Total Assets in million	234	170	181	113	115
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-18	-12	-45	-40	-66
Annual Return On Assets	-7.61 %	-7.02 %	-24.61 %	-35.77 %	-57.54 %

TARA's 5 Years Annual ROA >> Back to TARA Management Effectiveness >> Compare TARA ROA to its Competitors

More Return On Assets Ratios
TARA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TARA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TARA's Competitors
Subscribers only: Roa for Protara Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for TARA's Customers

You may also want to know
TARA's Roi	TARA's Inventory Turnover Ratio	TARA's Growth Rates	TARA's Dividend Comparisons
	TARA's Profitability Ratios	TARA's Asset Turnover Ratio	TARA's Dividend Growth
TARA's Roe	TARA's Valuation Ratios	TARA's Financial Strength Ratios	TARA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:10:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.